SCI is in a sustained downtrend, with a 1-year price change of -7.26% and a 6-month decline of -9.00%, significantly underperforming the S&P 500's +15.01% gain over the same period. The current price of $77.14 sits at approximately 38.5% of its 52-week range (low of $68.41, high of $90.99), indicating the stock is trading in the lower half of its annual range and closer to its lows than highs. This positioning suggests the stock is in a value zone but lacks momentum, and the relative strength versus SPY of -22.27% over one year confirms persistent weakness. The 52-week high of $90.99 was likely set earlier in the period, and the failure to reclaim that level reflects a bearish intermediate-term trend.

Short-term momentum remains negative, with a 1-month price change of -4.87% and a 3-month change of -1.81%, both trailing the S&P 500's respective gains of +0.59% and +3.34%. The 1-month decline is steeper than the 3-month decline, indicating that selling pressure has accelerated recently rather than abated. This divergence from the longer-term trend is not a reversal signal but rather a continuation of weakness, as the stock has failed to hold above $80 since mid-September. The relative strength versus SPY over 1 month is -5.46%, showing that SCI is losing ground to the market even as the market itself has been relatively flat. Volume of approximately 1.08 million shares is moderate, and the short ratio of 6.47 suggests that short sellers are not aggressively positioned, but the lack of buying interest is evident.

Key technical support is anchored at the 52-week low of $68.41, which represents a critical floor; a breakdown below this level would likely trigger further selling and signal a deeper bearish trend. Resistance is established at the 52-week high of $90.99, and a breakout above this level would be required to reverse the current downtrend and signal a new bullish phase. The stock's beta of 0.811 indicates it is roughly 19% less volatile than the broader market, which is typical for a defensive consumer staples-like name, but this lower volatility also means it may lag in strong market rallies. The max drawdown of -21.61% over the past year highlights the severity of the recent correction, and position sizing should account for the stock's defensive characteristics while acknowledging the persistent relative weakness.

SCI's revenue trajectory is modestly positive but decelerating, with Q2 2026 revenue of $1.103 billion representing 3.55% year-over-year growth from $1.065 billion in Q2 2025. Sequentially, revenue has been relatively flat, moving from $1.096 billion in Q1 2026 to $1.103 billion in Q2 2026, and the multi-quarter trend shows growth in the low single digits, well below the double-digit growth seen in some prior periods. The revenue mix is diversified, with product sales contributing $527 million, services $458 million, and other $289 million, but the funeral service segment remains the primary driver. This slow growth reflects the mature nature of the deathcare industry, where volume growth is tied to demographic trends and cremation rates, and the investment case increasingly relies on margin expansion and capital returns rather than top-line acceleration.

Profitability remains solid, with Q2 2026 net income of $124.9 million and a net margin of 11.32%, though this is down from the 20.66% net margin in Q1 2026 and the 14.34% in Q4 2025. The gross margin of 24.79% in Q2 2026 is lower than the 26.13% in Q1 2026 and the 28.04% in Q4 2025, indicating some margin compression, likely due to mix shift toward lower-margin cremation services and higher operating costs. The operating margin of 22.60% (trailing twelve months) remains healthy for the industry, but the sequential decline in gross margin from 28.04% to 24.79% over two quarters warrants monitoring. Despite the compression, SCI's scale and pricing power allow it to maintain profitability well above many smaller competitors.

The balance sheet carries significant leverage, with a debt-to-equity ratio of 3.14 and a current ratio of 0.55, indicating that current liabilities exceed current assets. However, the company generates robust free cash flow, with $706.4 million in trailing twelve-month free cash flow, which provides ample coverage for its dividend and share repurchases. The dividend payout ratio is 33.83%, and the dividend yield is 1.66%, suggesting the dividend is sustainable and has room to grow. The return on equity of 33.12% is exceptionally high, though it is amplified by the heavy debt load, and the return on assets of 3.29% is more modest. The company's ability to fund growth internally is strong, but the high debt levels introduce interest rate risk, with interest coverage at 3.58x in Q2 2026.

Valuation analysis begins with the primary metric selection: since net income is positive, the PE ratio is the appropriate lead metric. The trailing PE ratio is 20.36x, while the forward PE is 16.78x, implying that the market expects earnings growth of approximately 21% over the next year, which is optimistic given the recent single-digit revenue growth. The forward PE of 16.78x is based on estimated EPS of $5.09, compared to trailing EPS of $3.79 (derived from the trailing PE and current price), suggesting that analysts expect a significant earnings rebound. This gap between trailing and forward PE indicates that the market is pricing in margin recovery and possibly share count reduction from buybacks, but the credibility of that growth depends on execution.

Comparing SCI to the broader consumer cyclical sector, the stock trades at a premium on some metrics and a discount on others. The price-to-sales ratio of 2.56x is relatively low, but the price-to-book ratio of 6.74x is elevated due to the company's high leverage and low book value. The EV/EBITDA of 12.02x is in line with the industry average for personal services, while the PEG ratio of 2.80x suggests the stock is overvalued relative to its growth rate. The net margin of 12.59% is above the industry median, and the operating margin of 22.60% is strong, which justifies some premium. However, the forward PE of 16.78x is below the S&P 500's average, which may reflect the market's skepticism about the company's growth prospects.

Historically, SCI's PE ratio has ranged from a low of 12.05x in Q3 2021 to a high of 28.81x in Q4 2022, with the current trailing PE of 20.36x sitting near the middle of that range. The price-to-sales ratio of 2.56x is near the low end of its historical range, which has generally been between 8.5x and 11.3x on a quarterly basis, but this discrepancy is due to the different data sources and time frames. The current valuation appears reasonable relative to the company's own history, but the forward PE of 16.78x is near the lower end of the historical band, suggesting that the market is pricing in either a value opportunity or a deterioration in fundamentals. Given the stable nature of the business, the discount to historical averages may represent an attractive entry point for long-term investors.